Page last updated: 2024-11-12
woodfordin c
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
woodfordin C: structure given in first source; macro-ring tannin dimer with anti-tumor activity from Woodfordia fruticosa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Woodfordia | genus | A plant genus of the family LYTHRACEAE. Members contain woodfordins.[MeSH] | Lythraceae | The loosestrife plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. Members are mainly herbs and many of them contain ALKALOIDS.[MeSH] |
| Woodfordia fruticosa | species | [no description available] | Lythraceae | The loosestrife plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. Members are mainly herbs and many of them contain ALKALOIDS.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16131173 |
| MeSH ID | M0180024 |
Synonyms (3)
| Synonym |
|---|
| 126347-63-5 |
| woodfordin c |
| woodfruticosin |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.40) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||